Declared Dividend • May 23
Dividend of CN¥0.80 announced Shareholders will receive a dividend of CN¥0.80. Ex-date: 28th May 2026 Payment date: 28th May 2026 Dividend yield will be 3.2%, which is higher than the industry average of 2.6%. Sustainability & Growth Dividend is well covered by both earnings (46% earnings payout ratio) and cash flows (44% cash payout ratio). The dividend has increased by an average of 28% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 36% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Announcement • Apr 16
Zhejiang NHU Company Ltd., Annual General Meeting, May 15, 2026 Zhejiang NHU Company Ltd., Annual General Meeting, May 15, 2026, at 14:30 China Standard Time. Location: The Company's Meeting Room, Xinchang County, Zhejiang China Announcement • Mar 31
Zhejiang NHU Company Ltd. to Report Q1, 2026 Results on Apr 29, 2026 Zhejiang NHU Company Ltd. announced that they will report Q1, 2026 results on Apr 29, 2026 Announcement • Dec 31
Zhejiang NHU Company Ltd. to Report Fiscal Year 2025 Results on Apr 16, 2026 Zhejiang NHU Company Ltd. announced that they will report fiscal year 2025 results on Apr 16, 2026 Announcement • Sep 30
Zhejiang NHU Company Ltd. to Report Q3, 2025 Results on Oct 29, 2025 Zhejiang NHU Company Ltd. announced that they will report Q3, 2025 results on Oct 29, 2025 Announcement • Sep 16
Zhejiang Nhu Company Ltd. Approves Interim Dividend for 2025 Zhejiang NHU Company Ltd. held its 2nd Extraordinary General Meeting of 2025 on 12 September 2025, approved interim Cash dividend/10 shares (tax included): CNY2.00000000 for 2025. Announcement • Aug 29
Zhejiang Nhu Company Ltd. Proposes Interim Cash Dividend for 2025 Zhejiang NHU Company Ltd. proposed 2025 interim dividend at its EGM to be held on 12 September 2025, a Cash dividend (tax included) of CNY 2.00000000 per ten shares. Announcement • Jul 02
Zhejiang NHU Company Ltd. to Report First Half, 2025 Results on Aug 28, 2025 Zhejiang NHU Company Ltd. announced that they will report first half, 2025 results on Aug 28, 2025 Announcement • Apr 15
Zhejiang NHU Company Ltd., Annual General Meeting, May 08, 2025 Zhejiang NHU Company Ltd., Annual General Meeting, May 08, 2025, at 14:30 China Standard Time. Location: The Company's Meeting Room, Xinchang County, Zhejiang China Announcement • Mar 31
Zhejiang NHU Company Ltd. to Report Q1, 2025 Results on Apr 29, 2025 Zhejiang NHU Company Ltd. announced that they will report Q1, 2025 results on Apr 29, 2025 Announcement • Jan 16
Zhejiang Nhu Company Ltd. Announces Special Dividend of the Year 2024 of A Shares, Payable on 22 January 2025 Zhejiang NHU Company Ltd. announced special cash dividend/10 shares (tax included) of CNY 5.00000000 for year 2024 of A shares. Record date is 21 January 2025. Ex-date is 22 January 2025. Payment date is 22 January 2025. Announcement • Dec 31
Zhejiang NHU Company Ltd. to Report Fiscal Year 2024 Results on Apr 15, 2025 Zhejiang NHU Company Ltd. announced that they will report fiscal year 2024 results on Apr 15, 2025 Announcement • Dec 20
Zhejiang NHU Company Ltd. Proposes Special Cash Dividend for the Third Quarter of 2024 Zhejiang NHU Company Ltd. proposed special cash dividend of CNY 2.00 per 10 shares for the third quarter of 2024. Reported Earnings • Oct 24
Third quarter 2024 earnings released: EPS: CN¥0.58 (vs CN¥0.20 in 3Q 2023) Third quarter 2024 results: EPS: CN¥0.58 (up from CN¥0.20 in 3Q 2023). Revenue: CN¥5.94b (up 65% from 3Q 2023). Net income: CN¥1.79b (up 189% from 3Q 2023). Profit margin: 30% (up from 17% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 6.6% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has increased by 3% per year, which means it is well ahead of earnings. Valuation Update With 7 Day Price Move • Sep 30
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to CN¥22.57, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 16x in the Chemicals industry in China. Total returns to shareholders of 9.6% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥43.71 per share. Announcement • Sep 30
Zhejiang NHU Company Ltd. to Report Q3, 2024 Results on Oct 24, 2024 Zhejiang NHU Company Ltd. announced that they will report Q3, 2024 results on Oct 24, 2024 Reported Earnings • Aug 23
Second quarter 2024 earnings released: EPS: CN¥0.43 (vs CN¥0.27 in 2Q 2023) Second quarter 2024 results: EPS: CN¥0.43 (up from CN¥0.27 in 2Q 2023). Revenue: CN¥5.35b (up 41% from 2Q 2023). Net income: CN¥1.33b (up 59% from 2Q 2023). Profit margin: 25% (up from 22% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 9.3% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings. Announcement • Jun 29
Zhejiang NHU Company Ltd. to Report First Half, 2024 Results on Aug 23, 2024 Zhejiang NHU Company Ltd. announced that they will report first half, 2024 results on Aug 23, 2024 Announcement • May 25
Zhejiang NHU Company Ltd. Proposes Final Cash Dividend (A Shares) for the Year 2023, Payable on 29 May 2024 Zhejiang NHU Company Ltd. Proposed final cash dividend (A shares) (tax included) of CNY 4.50000000 per ten shares for the year 2023. Record date: 28 May 2024, Ex-date: 29 May 2024, Payment date: 29 May 2024. Net cash dividend/10 shares after tax: CNY 4.05000000 (CNY 4.50000000- CNY 0.45000000). Reported Earnings • Apr 24
Full year 2023 earnings released: EPS: CN¥0.88 (vs CN¥1.17 in FY 2022) Full year 2023 results: EPS: CN¥0.88 (down from CN¥1.17 in FY 2022). Revenue: CN¥15.1b (down 5.1% from FY 2022). Net income: CN¥2.70b (down 25% from FY 2022). Profit margin: 18% (down from 23% in FY 2022). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has fallen by 12% per year whereas the company’s share price has fallen by 13% per year. Announcement • Apr 23
Zhejiang NHU Company Ltd., Annual General Meeting, May 15, 2024 Zhejiang NHU Company Ltd., Annual General Meeting, May 15, 2024, at 14:30 China Standard Time. Location: The Company's Meeting Room, Xinchang County, Zhejiang China Announcement • Mar 30
Zhejiang NHU Company Ltd. to Report Q1, 2024 Results on Apr 30, 2024 Zhejiang NHU Company Ltd. announced that they will report Q1, 2024 results on Apr 30, 2024 Announcement • Dec 29
Zhejiang NHU Company Ltd. to Report Fiscal Year 2023 Results on Apr 23, 2024 Zhejiang NHU Company Ltd. announced that they will report fiscal year 2023 results on Apr 23, 2024 Reported Earnings • Oct 27
Third quarter 2023 earnings released: EPS: CN¥0.20 (vs CN¥0.26 in 3Q 2022) Third quarter 2023 results: EPS: CN¥0.20 (down from CN¥0.26 in 3Q 2022). Revenue: CN¥3.59b (down 2.7% from 3Q 2022). Net income: CN¥618.0m (down 23% from 3Q 2022). Profit margin: 17% (down from 22% in 3Q 2022). The decrease in margin was primarily driven by lower revenue. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has fallen by 7% per year whereas the company’s share price has fallen by 8% per year. Announcement • Sep 30
Zhejiang NHU Company Ltd. to Report Q3, 2023 Results on Oct 27, 2023 Zhejiang NHU Company Ltd. announced that they will report Q3, 2023 results on Oct 27, 2023 Announcement • Sep 21
Zhejiang NHU Company Ltd. Announces Executive Appointments Zhejiang NHU Company Ltd. at the Extraordinary General Meeting of 2023 on 19 September 2023 approved election of non-independent directors, cumulative voting system applicable: Yu Hongwei; Election of independent directors, cumulative voting system applicable: Shen Yuping, Wan Feng, Wang Yang; Election of non-employee supervisors, cumulative voting system applicable: Zhao Jia and Wang Xiaobi. Reported Earnings • Aug 30
Second quarter 2023 earnings released: EPS: CN¥0.27 (vs CN¥0.33 in 2Q 2022) Second quarter 2023 results: EPS: CN¥0.27 (down from CN¥0.33 in 2Q 2022). Revenue: CN¥3.81b (down 2.6% from 2Q 2022). Net income: CN¥840.1m (down 17% from 2Q 2022). Profit margin: 22% (down from 26% in 2Q 2022). The decrease in margin was primarily driven by lower revenue. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 13% per year, which means it is performing significantly worse than earnings. Announcement • Jun 09
Zhejiang NHU Company Ltd. Announces Final Dividend on A Shares for the Year 2022, Payable on June 14, 2023 Zhejiang NHU Company Ltd. announced final cash dividend/10 shares (tax included) of CNY 5.00000000 on A shares for the year 2022. Record date is June 13, 2023. Ex-date is May June 14, 2023. Payment date is June 14, 2023. Announcement • May 23
Zhejiang NHU Company Ltd. Approves Cash Dividend for 2022 Zhejiang NHU Company Ltd. at its Annual General Meeting of 2022 held on 19 May 2023, approved cash dividend/10 shares (tax included): CNY 5.00000000. Reported Earnings • Apr 21
First quarter 2023 earnings released: EPS: CN¥0.21 (vs CN¥0.39 in 1Q 2022) First quarter 2023 results: EPS: CN¥0.21 (down from CN¥0.39 in 1Q 2022). Revenue: CN¥3.61b (down 16% from 1Q 2022). Net income: CN¥643.2m (down 47% from 1Q 2022). Profit margin: 18% (down from 28% in 1Q 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings. Reported Earnings • Feb 25
Full year 2022 earnings released: EPS: CN¥1.18 (vs CN¥1.40 in FY 2021) Full year 2022 results: EPS: CN¥1.18 (down from CN¥1.40 in FY 2021). Revenue: CN¥15.9b (up 7.7% from FY 2021). Net income: CN¥3.64b (down 16% from FY 2021). Profit margin: 23% (down from 29% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 14% p.a. on average during the next 2 years, compared to a 17% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth. Reported Earnings • Oct 27
Third quarter 2022 earnings released: EPS: CN¥0.26 (vs CN¥0.31 in 3Q 2021) Third quarter 2022 results: EPS: CN¥0.26 (down from CN¥0.31 in 3Q 2021). Revenue: CN¥3.69b (up 13% from 3Q 2021). Net income: CN¥797.2m (down 17% from 3Q 2021). Profit margin: 22% (down from 30% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has only increased by 9% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Oct 25
Investor sentiment deteriorated over the past week After last week's 17% share price decline to CN¥18.31, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 21x in the Pharmaceuticals industry in China. Total returns to shareholders of 43% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥16.65 per share. Reported Earnings • Aug 25
Second quarter 2022 earnings released: EPS: CN¥0.33 (vs CN¥0.42 in 2Q 2021) Second quarter 2022 results: EPS: CN¥0.33 (down from CN¥0.42 in 2Q 2021). Revenue: CN¥3.91b (up 10% from 2Q 2021). Net income: CN¥1.01b (down 21% from 2Q 2021). Profit margin: 26% (down from 36% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 12%, compared to a 23% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has only increased by 14% per year, which means it is significantly lagging earnings growth. Reported Earnings • Apr 29
First quarter 2022 earnings released: EPS: CN¥0.47 (vs CN¥0.44 in 1Q 2021) First quarter 2022 results: EPS: CN¥0.47 (up from CN¥0.44 in 1Q 2021). Revenue: CN¥4.31b (up 15% from 1Q 2021). Net income: CN¥1.20b (up 5.9% from 1Q 2021). Profit margin: 28% (down from 30% in 1Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 7.4%, compared to a 25% growth forecast for the industry in China. Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has only increased by 18% per year, which means it is significantly lagging earnings growth. Reported Earnings • Apr 16
Full year 2021 earnings released: EPS: CN¥1.68 (vs CN¥1.38 in FY 2020) Full year 2021 results: EPS: CN¥1.68 (up from CN¥1.38 in FY 2020). Revenue: CN¥14.8b (up 44% from FY 2020). Net income: CN¥4.32b (up 21% from FY 2020). Profit margin: 29% (down from 35% in FY 2020). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 7.6%, compared to a 28% growth forecast for the pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 22% per year and the company’s share price has also increased by 22% per year. Reported Earnings • Mar 02
Full year 2021 earnings: EPS in line with expectations, revenues disappoint Full year 2021 results: EPS: CN¥1.67 (up from CN¥1.38 in FY 2020). Revenue: CN¥14.8b (up 43% from FY 2020). Net income: CN¥4.31b (up 21% from FY 2020). Profit margin: 29% (down from 35% in FY 2020). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 4.4%. Over the next year, revenue is forecast to grow 5.1%, compared to a 25% growth forecast for the pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has increased by 30% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • Nov 01
Third quarter 2021 earnings released: EPS CN¥0.38 (vs CN¥0.28 in 3Q 2020) The company reported a solid third quarter result with improved earnings and revenues, although profit margins were weaker. Third quarter 2021 results: Revenue: CN¥3.26b (up 50% from 3Q 2020). Net income: CN¥957.6m (up 32% from 3Q 2020). Profit margin: 29% (down from 34% in 3Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has increased by 29% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • Aug 20
Second quarter 2021 earnings released: EPS CN¥0.49 (vs CN¥0.51 in 2Q 2020) The company reported a mediocre second quarter result with weaker earnings and profit margins, although revenues improved. Second quarter 2021 results: Revenue: CN¥3.51b (up 31% from 2Q 2020). Net income: CN¥1.27b (down 2.8% from 2Q 2020). Profit margin: 36% (down from 49% in 2Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has increased by 29% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • Apr 29
First quarter 2021 earnings released: EPS CN¥0.53 (vs CN¥0.42 in 1Q 2020) The company reported a solid first quarter result with improved earnings and revenues, although profit margins were weaker. First quarter 2021 results: Revenue: CN¥3.74b (up 43% from 1Q 2020). Net income: CN¥1.14b (up 26% from 1Q 2020). Profit margin: 30% (down from 34% in 1Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has increased by 25% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • Apr 01
Full year 2020 earnings released: EPS CN¥1.66 (vs CN¥1.01 in FY 2019) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: CN¥10.3b (up 35% from FY 2019). Net income: CN¥3.56b (up 64% from FY 2019). Profit margin: 35% (up from 28% in FY 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has increased by 26% per year, which means it is tracking significantly ahead of earnings growth. Is New 90 Day High Low • Feb 20
New 90-day high: CN¥42.75 The company is up 28% from its price of CN¥33.31 on 20 November 2020. The Chinese market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 7.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥19.02 per share. Is New 90 Day High Low • Jan 20
New 90-day high: CN¥41.05 The company is up 46% from its price of CN¥28.06 on 23 October 2020. The Chinese market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥19.55 per share. Valuation Update With 7 Day Price Move • Jan 07
Investor sentiment improved over the past week After last week's 17% share price gain to CN¥39.29, the stock is trading at a trailing P/E ratio of 24.7x, up from the previous P/E ratio of 21.2x. This compares to an average P/E of 33x in the Pharmaceuticals industry in China. Total returns to shareholders over the past three years are 64%. Is New 90 Day High Low • Dec 31
New 90-day high: CN¥33.68 The company is up 13% from its price of CN¥29.79 on 30 September 2020. The Chinese market is up 6.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is flat over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥19.92 per share. Is New 90 Day High Low • Dec 09
New 90-day high: CN¥33.40 The company is up 6.0% from its price of CN¥31.46 on 11 September 2020. The Chinese market is up 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥15.70 per share. Reported Earnings • Oct 29
Third quarter earnings released Over the last 12 months the company has reported total profits of CN¥3.40b, up 51% from the prior year. Total revenue was CN¥9.33b over the last 12 months, up 21% from the prior year. Analyst Estimate Surprise Post Earnings • Oct 29
Third-quarter earnings released: Revenue misses expectations Third-quarter revenue missed analyst estimates by 31% at CN¥2.18b. Revenue is forecast to grow 45% over the next year, compared to a 30% growth forecast for the Pharmaceuticals industry in China. Is New 90 Day High Low • Oct 20
New 90-day low: CN¥28.51 The company is down 5.0% from its price of CN¥30.12 on 22 July 2020. The Chinese market is flat over the last 90 days, indicating the company underperformed over that time. However, its price trend is similar to the Pharmaceuticals industry, which is also down 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥16.10 per share.